The use of Ferinject® (ferric carboxymaltase) in the treatment of iron deficiency in patients with renal anaemia Dr D Farrugia Dr S Ramakrishna E Gibson.

Slides:



Advertisements
Similar presentations
Drug Calculations CWFS F1 Programme Safe Prescribing Module
Advertisements

Extent and Management of Anaemia in Transplant Patients EDTNA/ERCA Anaemia&Transplant Interest Groups.
Chapter 3: Clinical Indicators and Preventive Care 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Iron Repletion in ESRD Saleem Bharmal 2/9/10.
Transfusion Quiz “Their Lives in Your Hands” Doctors.
Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.
1 Dosage Calculation Review Review based on required readings selected from: Pickar, G. (2007). Dosage calculation: A ratio-proportion approach (2nd ed.).
IV Flow Rates –BASED ON BODY WEIGHT
Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.
UK Renal Registry 17th Annual Report Figure 9.1. Median height z-scores for transplant patients
UK Renal Registry 16th Annual Report Figure Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2012.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
UK Renal Registry 17th Annual Report Figure 8.1. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
Audit of intravenous fluid prescribing and biochemical monitoring in children undergoing appendicectomy. Dr Rosie Snaith Dr J. Peutrell. June 2007.
Treatment protocol. Who will be treated? People will be treated based only on the results of diagnostic tests performed, not on any other clinical assessment.
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
How to manage anaemia in HD patients
Causes Blood loss – usually from uterus or GI tract Increased demands such as growth and pregnancy Decreased absorption – post gastrectomy, Coeliac disease.
© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.
Anaemia Management Breakthrough Collaborative. Best scientific knowledge? Kidney senses tissue oxygen tension EPO Bone marrow stimulated Increased red.
Scottish Renal Registry Report 2009 Published by the Information Services Division (ISD Scotland), Common Services Agency for NHSScotland, 1 South Gyle.
Research Project for Dialysis Patients with a Hgb >13 for 2005 Researched, Edited, and Presented by Mindy Huttu, Anatole Besarab, and Stan Frinak.
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
CHAPTER 6: MANAGEMENT OF ANAEMIA IN PATIENTS ON DIALYSIS Philip N. Jeremiah Bee Boon Cheak Ghazali B Ahmad Lim Soo Kun Zawawi B Nordin Source: 21 st MDTR.
UK Renal Registry 15th Annual Report Figure 6.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2011.
Prevalence and management of cardiovascular risks in renal transplant recipients Dr VS Aithal Consultant Nephrologist Swansea.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
© ANZDATA Registry Prevalence and Incidence End Stage Renal Failure - Australia ( ) Per Million Functioning Transplant (259) New Pts (82) Deaths.
UK Renal Registry 16th Annual Report Figure Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
UK Renal Registry 16th Annual Report Figure Median height z-scores for transplant patients
UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients
Figures from Dialysis and kidney transplantation in Australia 1991–2010.
Update The 2 week rule for colorectal cancer Mr Iain Jourdan MS FRCS Director of Surgery Royal Surrey County Hospital.
Renal Transplantation at Shrewsbury and Telford NHS Trust. Sue Dean – Transplant Nurse. Suresh Ramadoss – Nephrologist and Transplant Lead. 9/7/15.
Chronic Haemodialysis therapy in octogenarians with ESRF: demographics and outcomes from a single centre in England Dr Punit Yadav Dr Jyoti Baharani.
Intrathecal Morphine Usage in Hepatobiliary Surgery Dr David Cosgrave Dr Era Soukhin Dr Anand Puttapa Dr Niamh Conlon.
JUST GIVE IT: a 2 phase study to audit the Immediate Management of Patients with Proven or Suspected Neutropenic Sepsis by Ally Gruber Acute Oncology Clinical.
Iron as a Treatment: Successes and Failures. What next? Christopher J Earley MB, BCh, PhD, FRCP(I) Professor Department of Neurology Johns Hopkins School.
Introduction Iron deficiency is commonly identified in endurance runners due to prolonged training and repeated ground impacts causing iron losses through.
Aetiology of preoperative anaemia in patients undergoing elective cardiac surgery Jacob Abhrahm 1,Romi Sinha 2,Kathryn Robinson 3, David Cardone 1 1 Department.
PREOPERATIVE ANAEMIA PATHWAY CARDIAC SURGERY CARDIFF AND VALE UHB
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
Medical Directorate, National Kidney Foundation, Singapore
Intravenous Iron in Palliative Care
Mansoura International Hospital Mansoura International Hospital
UK Renal Registry 18th Annual Report
The aminoglycoside antibiotics
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
Administration of Undiluted Ferrlecit 12.5 mg/ml
QIP: Intravenous Iron Service for Renal Anaemia at SaTH
Chapter 2: Clinical Indicators and Preventive Care
Medical Dosage Calculations A Dimensional Analysis Approach
Paediatric Daily Fluid Prescription & Balance Chart 2017
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Iron status and iron supplementation in peritoneal dialysis patients
Iron Deficiency Anemia
Volume 2: End-Stage Renal Disease
Iron Deficiency Anemia
Clinical pharmacy laboratory/4 th Class Anemias and blood disorders
UK IT Industry Awards – UK Public Sector Project of the Year
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Recent experience with high-dose intravenous iron administration
UK Renal Registry 14th Annual Report
Volume 55, Issue 5, Pages (May 1999)
Volume 75, Issue 9, Pages (May 2009)
Stock and Flow of Haemodialysis Patients Australia
Stock and Flow of Peritoneal Dialysis Patients Australia
NEW INSULIN ORDER SETS (NON-ICU AREAS)
Presentation transcript:

The use of Ferinject® (ferric carboxymaltase) in the treatment of iron deficiency in patients with renal anaemia Dr D Farrugia Dr S Ramakrishna E Gibson Royal Shrewsbury Hospital, SaTH

Introduction Ferinject® has been used in our unit from March In this audit we will look at the patients who received Ferinject® in our unit from March 2009 to April In this period 105 patients have received Ferinject® in our unit.

Aims  Analyze demographics of the patients receiving Ferinject®  Analyze the pre and post ferritin and Hb levels  Analyze the proportion of patients receiving Ferinject® and EPO preparations  Analyze haemoglobin change in patients on EPO vs not on EPO at time of Ferinject® infusion  Follow up patients

Method A list of patients treated with IV Ferinject® since March 2009 had been recorded by our anaemia team. The results of each patient were looked up in renal plus and review results databases and recorded on an excel sheet.

Ferinject® Administration The dose of Ferinject required is calculated using the following formula:

Ferinject® Administration  In our unit Ferinject is given intravenously using an Alaris pump over minutes.  The maximum dose of Ferinject is 15mg per kg body weight.  The maximum single dose of Ferinject is 1000mg per week.

Results  Demographics  Ferritin levels  EPO  Haemoglobin change in patients on EPO vs not on EPO at time of Ferinject® infusion  Follow-up of patients

Demographics Age: The average age is 73. Range was from 24 to 92 years.

Demographics

Demographics

Ferritin levels

105 patients Ferritin 0-100: 94 patients 89.5% Ferritin : 9 patients 8.5% Ferritin >200: 1 patient 1% Ferritin unknown: 1 patient 1% Ferritin not checked: 1 patient Ferritin not checked: 1 patient Ferritin <100: 1 patient 11.1%/(0.9%) Ferritin <100: 6 patients 6.4%/(5.7%) Ferritin not processed: 1 patient 1.1%/(1%) Ferritin >200: 6 patients 66.7%/(5.7%) Ferritin >200: 71 patients 75.5%/(67.6%) Ferritin : 10 patients 10.6%/(9.5%) Ferritin not checked: 2 patients 22.2%/(1.9%) Ferritin not checked: 6 patients 6.4%/(5.7%) Post infusion Ferritin levels pre and post Ferinject ® Infusion

Ferritin levels

 In 6 patients ferritin levels were above 800ng/ml after 1 dose of Ferinject® infusion.  In 15 patients ferritin levels were above 500ng/ml after 1 dose of Ferinject® infusion.

Haemoglobin levels

*No change in Hb – Hb stayed within 1g/dL above or below the pre Ferinject® level

EPO 105 patients received Ferinject® 31 patients NOT had EPO 74 patients HAD EPO 40 patients had EPO PRIOR to Ferinject® 18 patients had EPO at the SAME* time as Ferinject® 16 patients had EPO AFTER Ferinject® *Patient being given simultaneously Ferinject® and EPO means that EPO was started up to 1 month before or after Ferinject® was given.

EPO

Haemoglobin change in patients not on EPO at time of Ferinject® group (n = 65 patients) (Patients not on EPO include patients who never received EPO, were not on EPO at time of Ferinject® infusion or started EPO at the same tine as Ferinject® infusion)

Haemoglobin change in patients not on EPO at time of Ferinject® group (n = 65 patients) (Patients not on EPO include patients who never received EPO, were not on EPO at time of Ferinject® infusion or started EPO at the same tine as Ferinject® infusion)

Haemoglobin change in patients on EPO at time of Ferinject® group (n = 40 patients)

Follow-up Further doses of Ferinject®  12 patients had further doses of Ferinject® (and another one possibly had further doses prescribed by the haematologists)  Of these patients who had repeat doses 9 patients (75%) had 1 further dose, 2* patients (16.7%) had 2 further doses, 1 (8.3%) patient had 4 further doses *1 of the patient who had 2 further doses was actively bleeding at the time.

Follow-up If the patient who was actively bleeding is excluded as it is likely to give skewed data, the average interval between Ferinject doses was 7.33 months

Follow-up of patients who received Ferinject® 96 patients PREDIALYSIS/ CONSERVATIVE 3 patients TRANSPLANT 1 patient changed to HAEMODIALYSIS 1 patient had 1 FURTHER DOSE 1 patient DIED 11 (+1) patients FURTHER DOSE 6 patients DIED 2 patients PERITONEAL DIALYSIS 9 patients HAEMODIALYSIS 2 patients DIED 1 patient HAEMODIALYSIS 1 patient DIED 2 patients HAEMODIALYSIS 105 patients 6 patients PERITONEAL DIALYSIS

Thank-you Any questions?